US20040229909A1 - Antiviral agent - Google Patents

Antiviral agent Download PDF

Info

Publication number
US20040229909A1
US20040229909A1 US10/485,394 US48539404A US2004229909A1 US 20040229909 A1 US20040229909 A1 US 20040229909A1 US 48539404 A US48539404 A US 48539404A US 2004229909 A1 US2004229909 A1 US 2004229909A1
Authority
US
United States
Prior art keywords
optionally substituted
same
compound
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/485,394
Other languages
English (en)
Inventor
Ryuichi Kiyama
Yasuhiko Kanda
Yukio Tada
Toshio Fujishita
Takashi Kawasuji
Shozo Takechi
Masahiro Fuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27347328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040229909(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Assigned to SHIONOGI & CO., LTD. reassignment SHIONOGI & CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FUJI, MASAHIRO, FUJISHITA, TOSHIO, KANDA, YASUHIKO, KAWASUJI, TAKASHI, KIYAMA, RYUICHI, TADA, YUKIO, TAKECHI, SHOZO
Publication of US20040229909A1 publication Critical patent/US20040229909A1/en
Priority to US14/603,979 priority Critical patent/US9572813B2/en
Priority to US15/356,343 priority patent/US20170066754A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to an antiviral agent, especially, a compound having an ⁇ -hydroxy- ⁇ , ⁇ unsatutared keone as a partial structure, and a pharmaceutical composition as an integrase inhibitor containing the same.
  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • the therapeutic agent for AIDS is mainly selected from the group of reverse transcriptase inhibitors (e.g., AZT, 3TC) and protease inhibitors (e.g., Indinavir), but they are proved to be accompanied by side effects such as nephropathy and the emergence of resistant viruses.
  • AZT reverse transcriptase inhibitors
  • Indinavir protease inhibitors
  • the development of anti-HIV agents having the other mechanism of action has been desired.
  • Examples of the integrase inhibitor include 1,3-dioxobutanoic acids and 1,3-propanediones described in WO99/50245, WO99/62520, WO99/62897, WO99/62513, WO00/39086, and WO01/00578.
  • Another integrase inhibitor is acrylic acid derivative described in WO01/17968.
  • the other recently reported types are aza-or polyazanaphthalenylcarboamide derivative described in WO2002/30426, WO2002/30930, WO2002/30931, and WO2002/36734.
  • a compound having a similar structure to the present invention compound is N-substituted-3-carboamide-4-hydroxy-5-oxo-3-pyrroline derivative with an anti-inflammatory effect described in Eur. J. Med. Chemical-Chim. Ther. (1979), 14(2), 189-190. Pharmazie (1997), 52(4), 276-278 discloses 1-methyl-4-arylcarbamido-2,3-dioxopyrrolidine derivative as an intermediate.
  • WO92/06954 discloses pyrolizinedione derivative with an inhibitory effect on aldose reductase. J. Med.
  • T'ai-wan K'o Hsueh (1997), 31(3-4), 130-135 discloses 3-hydroxy-7-(phenylmethoxy)-2-(2-quinolinyl)-4H-1-benzopyrane-4-one.
  • Examples of a compound having a structure of “4H-1-benzopyrane-4-one” include flavonoid derivative with anti-HIV activity described in ⁇ circle over (1) ⁇ J. Nat. Prod. (2001), 64(4), 546-548, ⁇ circle over (2) ⁇ Anticancer Res. (2000), 20(4), 2525-2536, ⁇ circle over (3) ⁇ WO98/11889, ⁇ circle over (4) ⁇ Pharmazie (1998), 53(8), 512-517, though the action of mechanism is not mentioned therein.
  • the present inventors have intensively studied to find a novel antiviral agent, the following compound (I), its prodrug, or a pharmaceutically acceptable salt or solvate thereof, possessing an integrase inhibitory activity;
  • R C and R D taken together with the neighboring carbon atoms may form a ring, and the ring may be a condensed ring;
  • Y is hydroxy, mercapto or amino;
  • Z is O, S or NH;
  • R A is shown by
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom; the broken line shows the presence or absence of a bond.
  • X is O, S or NH;
  • R B is a substituent selected from substitution group A) at least one of the ring formed by R C and R D , C ring or R B is substituted with a group of —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene;
  • Z 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—, —S—, —S O—, —SO 2 —, —SO 2 NR 2 —, —NR 2 SO 2 —, —O—, —NR 2 —, —NR 2 CO—, —CONR 2 —, —C( ⁇ O)—O—, —O—C( ⁇ O) or —CO—;
  • R 2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
  • the present inventors further found that the present invention compound and a pharmaceutical composition containing the same are useful as antivirus agent, anti-retrovirus agent, anti-HIV agent, anti-HTLV-1 (Human T cell leukemia virus type 1) agent, anti-FIV (Feline immunodeficiency virus) agent, and anti-SIV (Simian immunodeficiency virus) agent, esp., anti-HIV agent and an integrase inhibitor, whereby to achieve the present invntion.
  • the present invntion provides the present invention compound, its prodrug, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition containing the same as an active ingredient, antivirus agent, anti-HIV agent, an integrase inhibitor, and anti-HIV mixture.
  • AIDS related complication ARC AIDS related complication ARC
  • PDL persistent generalized lymphadenopath(PGL)
  • Kaposi sarcoma pneumocystis carini pneumonia
  • sudden thrombocy topenic purpura AIDS related neurological symptom, for example, AIDS dementia complications AIDS-associated encephalopathy multiple sclerosis or tropical spastic paraparesis, and anti-HIV antibody positive and HIV positive symptom in asymptomatic patients.
  • the present invntion relates to:
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is non-substituted N atom; the broken line shows the presence or absence of a bond.
  • X is O, S or NH;
  • R B is a substituent selected from substitution group A) at least one of the ring formed by R C and R D , C ring or R B is substituted with a group of —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene;
  • Z 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—, —S—, —S O—, —SO 2 —, —SO 2 NR 2 —, —NR 2 SO 2 —, —O—, —NR 2 —, —NR 2 CO—, —CONR 2 —, —C( ⁇ O)—O—, —O—C( ⁇ O) or —CO—;
  • R 2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally
  • R 8 , R 9 and R 10 are each independently a non-interfering substituent; at least one of R E and R F is shown by —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R′ are the same as above (1)) and the other is a non-interfering substituent, or R E and R F taken together with the neighboring carbon atoms may form a ring shown by
  • R 11 to R 13 are each independently a non-interfering substituent, Z 1 , Z 2 , Z 3 and R 1 are the same as above (1)), its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R 11 to R 14 are each independently a non-interfering substituent, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R 9 , R 10 and R 15 are each independently a non-interfering substituent; R E and R F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring shown by
  • R 11 to R 14 are each independently a non-interfering substituent, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R 9 to R 15 are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof).
  • R 11 to R 14 are each independently a non-interfering substituent
  • R 9 and R 10 are each independently a non-interfering substituent; R F and R G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R 9 , R 10 , R F and R G are each independently a non-interfering substituent; the broken line(---) shows the presence or absence of a bond), its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • a method for prevention or treatment of AIDS or AIDS-related complication comprising administration of a pharmaceutical composition of any one of above (1) to (35).
  • R B is optionally substituted aryl, optionally substituted heteroaryl optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle
  • C ring is the same as above (1); Y and Z are the same as above; R 8 to R 10 are the same as above (14); W 1 is the same as above (20); R 16 is a non-interfering substituent),
  • C ring is the same as above (1); Y and Z are the same as above; R 8 to R 13 are the same as above (14); W 1 is the same as above (20)),
  • C ring is the same as above (1); Y and Z are the same as above; R 9 to R 1 4 is the same as above (16); W 1 is the same as above (20)),
  • C ring is the same as above (1); Y and Z are the same as above; W 1 is the same as above (20); R 9 and R 10 are the same as above (14); R 17 and R 18 are each independently a non-interfering substituent),
  • R 17 and R 18 are each independently a non-interfering substituent
  • C ring is the same as above (1); Y and Z are the same as above; R 9 and R 10 are the same as above (14); R 17 and R 18 are the same as defined above),
  • C ring is the same as above (1); Y and Z are the same as above; R 5 is the same as above (10); R 9 and R 10 are the same as above (14); R 17 and R 18 are the same as defined above),
  • C ring is the same as above (1); Y and Z are the same as above; R 5 and R 5 ′ are the same as above (27); R 9 and R 10 are the same as above (14))
  • C ring is the same as above (1); Y and Z are the same as above; R 9 and R 10 are the same as above (14); R 17 and R 18 are the same as above, the broken line(---) shows the presence or absence of a bond),
  • C ring is the same as above (1); Y and Z are the same as above; R 5 is the same as above (10); R 9 and R 10 are the same as above (14); R 17 and R 18 are the same as above, the broken line(---) shows the presence or absence of a bond),
  • C ring is the same as above (1); Y and Z are the same as above; R 5 is the same as above (10); R 9 and R 10 are the same as above (14); R 18 is the same as defined above);
  • R 8 to R 13 are hydrogens, Y is hydroxy, Z is O, W is —O—, and C ring is quinoline-2-yl) or the formula:
  • R 9 and R 10 are the same as above, R 17 is alkyl, R 18 is hydrogen,Y is hydroxy, Z is O, C ring is dihydropirimidine).
  • R 5 is hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxycarbonylalkyl or heteroarylalkyl, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R B is fran-2-yl; Z 1 and Z 3 are bonds; Z 2 is alkylene; R 1 is aryl optionally substituted with halogen; R 6 ,R 7 , R E and R F are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • X is O; Y is hydroxy; Z is b; R B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle; Z 1 , Z 2 , Z 3 and R 1 are the same as above (1); R 6 ,R 7 , R F and R G are each independently a non-interfering substituent), its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R B is fran-2-yl; Z 1 and Z 3 are bonds; 2 is alkylene; R 1 is aryl optionally substituted with halogen; R 6 ,R 7 , R F and R G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • R B is fran-2-yl; Z 1 and Z 3 are bonds; 2 is alkylene; R 1 is aryl optionally substituted with halogen; R 1 ,R 7 , R F and R G are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • C ring is optionally substituted pyridine-2-yl, optionally substituted pyrimidine-4-yl, optionally substituted 1,3,4-oxadiazole-2-yl, optionally substituted 1,2,4-triazole-3-yl or optionally substituted imidazole-2-yl, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • Z 1 and Z 3 are each independently a bond or alkylene; 2 is a bond or —O—; R 1 is optionally substituted aryl or optionally substituted heteroaryl, its prodrug or pharmaceutically acceptable salt or solvate thereof
  • C ring is pyrimidine-4-yl or 1,3,4-oxadiazole-2-yl;
  • Z 1 is a bond;
  • Z 2 is —O or alkylene;
  • Z 3 is a bond or alkylene;
  • R 1 is aryl optionally substituted with halogen;
  • R 3 ,R 4 and R 19 are hydrogens, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • each non-interfering substituent is independently selected from hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxy alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano
  • R c and RD taken together with the neighboring carbon atoms form 5-or 6-membered heterocycle which may contain 0 and/or N atom and be condesed with a benzene ring;
  • Y is hydroxy, mercapto or amino;
  • Z is O, S or NH R A is shown of the formula:
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is unsubstituted N atom the broken line shows the presence or absence of a bond.
  • R B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle); at least one of the ring formed by R C and R D , C ring and R B is substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—, —S—, —SO—, —SO 2 —, —SO 2 N(R 2 )—, —N(R 2 )SO 2 , —O—, —N(R 2 )—, —N(R 2 )CO—, —CON(R 2 )
  • the ring formed by R C and R D , C ring or R B is optionally substituted with 1 to 3 substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxycarbonylalkyl, heteroarylalkyl and hydroxy, at any position except where the above the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 are the same as defined above) locates, its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • substituents selected from hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxyalkyl, alkenyl, alkoxycarbonylalkyl, heteroarylalkyl and
  • a pharmaceutical composition comprising a compound of any one of above (38) to (99), its prodrug or pharmaceutically acceptable salt or solvate thereof.
  • [0205] (108) A method for prevention or treatment of AIDS or a AIDS-related complication which comprises administration of a compound of any one of (38) to (99).
  • a pharmaceutical composition as an integrase inhibitor comprising as an effective ingredient a compound of above (117).
  • R C and R D taken together with the neighboring carbon atoms may form a ring, and the ring may be a condensed ring,
  • Z is O, S or NH
  • R A is shown by the formula
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom,
  • X is O, S or NH
  • R B is a substituent selected from substitution group A,
  • At least one of the ring formed by R C and R D , C ring or R B is substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—, —S—, —SO—, —SO 2 —, —SO 2 NR 2 —, —NR 2 SO 2 —, —O—, —NR 2 —, —NR 2 CO—, —CONR 2 —, —C( ⁇ O)—O—, —O—C( ⁇ O) or —CO—; R 2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R 1 is optionally substituted ary
  • the ring formed by R C and R D , C ring or R B is optionally substituted with a non-interfering substituent at any possition other than that where the group of —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 is the same as defined above) locates,
  • substitution groupA consists of: hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkyl carbonyloxy, hydrazino, morpholino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted
  • the ring formed by R C and R D includes a 4- to 9-membered carbocycle or heterocycle, which may be condensed with the other ring (e.g., 4- to 9-membered carbocycle or heterocycle, or a condensed ring thereof).
  • Preferred is a 5- to 7-membered carbocycle or heterocycle, more preferred is 5-or 6-membered carbocycle or heterocycle, and their condensed ring with the other ring (e.g., 5-or 6-membered carbocycle or heterocycle).
  • Further preferred rings formed by R C and R D are the following cases.
  • the heteroaryl used below refers to a ring containing 1 to 4 hetero atom(s) (O, O or S).
  • the ring is 5-or 6-membered one which may contain a hetero atom(s),
  • the ring is 5-or 6-membered heterocycle containing a hetero atom(s),
  • the ring is 5-or 6-membered heterocycle which may contain O and/or N atom,
  • the ring is 5-or 6-membered heterocycle which contains O and/or N atom
  • the ring is 5-or 6-membered heterocycle which contains N atom
  • the ring is 5-or 6-membered heterocycle which contains O atom
  • the ring is 5-membered heterocycle which contains N atom
  • the ring is 6-membered heterocycle which contains O atom
  • the ring is 6-membered carbocycle
  • the ring is one of above 1) to 9) which is condensed with the other ring,
  • the ring is heterocycle which consists of the ring of above 1) to 9) condensed with a benzene ring.
  • R C and R D examples include the followings:
  • the ring is 5-membered N-containing heterocycle
  • the ring is 6-membered N-containing heterocycle
  • the ring is 6-membered O-containing heterocycle condensed with benzene ring, and
  • the ring is 6-membered N-containing heterocycle condensed with benzene ring
  • the ring formed by R C and R D may be substituted, at any substitutable position of C atom or N atom constructing the ring, with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 are the same as defined above.) or a non-interfering substituent.
  • the compound of the formula (I) is characterized in that at least one of the ring formed by R C and R D , C ring and R B is substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 —Z 3 and R 1 are the same as defined above.).
  • Examples of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 , and R 1 are the same as defined above.) include —R 1 , —CH 2 —R 1 , —CH ⁇ CH—R 1 , —CH(OH)—R 1 ,—S—R 1 , —SO—R 1 , —SO 2 —R 1 , —SO 2 NH—R 1 , —NHSO 2 —R one or 1 , —NH—R 1 , —NHCO—R 1 , —CONH—R 1 ,—C( ⁇ O)—O—R 1 ,—O—C( ⁇ O)—R 1 ,—CO—R 1 ,—C 2 H 4 —R 1 ,—CH ⁇ CH—CH 2 —R 1 ,—CH(O H)—CH 2 —R 1 , —S—CH 2 —R 1 , —SO—CH 2
  • Z 1 and Z 3 are bonds, Z 2 is a bond, —CO—, —O—, —S—, —SO 2 or lower alkylene (esp., —CH 2 —,—(CH 2 ) 2 —),
  • Z 1 and Z 3 are bonds
  • Z 2 is a bond, —CO—, —O—, —S—, —SO 2 or lower alkylene (esp., —CH 2 —,—(CH 2 ) 2 —)
  • R 1 is optionally substituted aryl or optionally substituted heteroaryl
  • Z 1 and Z 3 are bonds, Z 2 is —S 2 , —CH 2 or —C 2 H 4 -, R 1 is optionally substituted aryl (esp., phenyl),
  • Z 1 is a bond or alkylene
  • Z 3 is a bond
  • Z 2 is optionally substituted alkylene, alkenylene or —O—
  • R 1 is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted cycloalkyl
  • Z 1 is a bond or alkylene
  • Z 2 is a bond, alkylene, —SO 2 or —O—,
  • Z 2 is a bond, alkylene or —O—
  • Z 3 is a bond or alkylene
  • R 1 is optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl,
  • R 1 is optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle or optionally substituted aryl,
  • R 1 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocycle,
  • R 1 is optionally substituted aryl
  • Z 1 and Z 3 are bonds, Z 2 is alkylene, R 1 is optionally substituted aryl,
  • Z 1 is a bond or alkylene
  • Z 3 is a bond
  • Z 2 is optionally substituted alkylene, alkenylene, —S or —O—
  • R 1 is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted cycloalkyl
  • Z 1 and Z 3 are each independently a bond or alkylene;
  • Z 2 is a bond or —O—R 1 is optionally substituted aryl or optionally substituted heteroaryl,
  • R 1 is phenyl optionally substituted with halogen, Z 1 is a bond, Z 2 is alkylene or —O—, Z 3 is a bond or alkylene,
  • R 1 is 4-fluorophenyl, Z 1 is a bond, Z 2 is alkylene or —O—, Z 3 is a bond or alkylene.
  • Examples of the formula: —Z 1 —Z 2 —Z 3 —R 1 include phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-bromophenyl, 4-biphenyl, benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2,4-difluorobenzyl, 2,6-difluoro
  • C ring is N-containing aromatic heterocycle wherein at least one atom neighboring to the atom at the bonding-position is N atom the broken line shows the presence or absence of a bond
  • C ring is N-containing aromatic heterocycle wherein at least one atom neighboring to the atom at the bonding-position is N atom the broken line shows the presence or absence of a bond
  • heteroaryl wherein at least one atom neighboring to the atom at the bonding-position is non-substituted N atom.
  • C ring may contain a hetero atom(s) other than the N atom shown in the above formula.
  • the atoms constituting C ring include C, O, N and S.
  • the bonds constituting C ring include a single bond or double bond.
  • C ring is a monocyclic ring or condensed ring (e.g., di- to penta-cyclic condensed ring) and preferred is a monocyclic ring or di-cyclic condensed ring, and more preferred is a monocyclic ring.
  • a monocyclic heteroaryl of C ring means 5- to 8-membered heteroaryl wherein one atom neighboring to the atom at the bonding-position is non-substituted N atom and which may contain further 1 to 4 of O, S and/or N atom, and preferably 5-or 6-membered heteroaryl.
  • the examples include imidazole-2-yl, imidazole-4-yl, pyrazole-3-yl, triazole3-yl, tetrazole-5-yl, oxazole-2-yl, oxazole-4-yl, isoxazole-3-yl, thiazole-2-yl, thiazole-4-yl, 1,3,4-thiadiazole-2-yl, 1,2,4-thiadiazole-5-yl, 1,2,4-thiadiazole-3-yl, 1,3,4-oxadiazole-2-yl, 1,2,4-oxadiazole-5-yl, 1,2,4-oxadiazole-3-yl, isothiazole-3-yl, pyridine-2-yl, pyridazine-3-yl, pyradine-2-yl, pyrimidine-2-yl, pyrimidine-4-yl, and furazan-3-yl.
  • a condensed heteroaryl of C ring means the above monocyclic heteroaryl which is condensed with 1 to 4 of 5- to 8-membered aromatic carbocycle and/or with another 5- to 8-membered aromatic heterocycle optionally containing 1 to 4 of 0, S, and/or N atom(s).
  • the aromatic ring to be condensed is preferably 5-or 6-membered one, such as benzimidazole-2-yl, benzooxazole-2-yl, quinoxaline-2-yl, cinnoline-3-yl, quinazoline-2-yl, quinazoline-4-yl, quinoline-2-yl, phthalazine-1-yl, isoquinoline-1-yl, isoquinoline-3-yl, purine-2-yl, purine-6-yl, purine-8-yl, pteridine-2-yl, pteridine-4-yl, pteridine-6-yl, pteridine-7-yl, and phenantridine-6-yl.
  • benzimidazole-2-yl isoquinoline-1-yl, and isoquinoline-3-yl
  • quinoline-2-yl isoquinoline-1-yl, and isoquinoline-3-yl
  • More preferred is of the formula:
  • C ring may be substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 are the same as above) or a non-interfering substituent.
  • R n 0-1 (n is an integar more than 0) is R n 0 or R n 1 R n 0 means “non-substituted with R n ”, and R n 1 means “substituted with R n ”.
  • R C and R D taken together with the neighboring carbon atoms may form 5- to 6-membered heterocycle which may contain O and/or N atom and may be condensed with benzene ring;
  • Y is hydroxy, mercapto or amino;
  • Z is O, S or NH;
  • R A is the formula
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom, and the broken line shows the presence or absence of a bond
  • R B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle);
  • At least one of the ring formed by R C and R D , C ring or R B is substituted with a group of the formula; —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene; Z 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—,—S—, —SO—,—SO 2 —,—SO 2 NR 2 —,—NR 2 SO 2 —,—O—,—NR 2 —,—NR 2 C-,—CONR 2 —,—C( ⁇ O)—O—,—O—C( ⁇ O) or —CO—; R 2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl; R 1 is optionally substituted aryl, optionally substituted heteroaryl, optional
  • Furthre preferred are the followings:
  • R E and R F are a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 , the other is a non-interfering substituent or R E and R F taken together with the neighboring carbon atoms may form a ring of the formula
  • R C and R F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula:
  • R E and R F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula
  • R E and R F are each independently a non-interfering substituent or taken together with the neighboring carbon atoms may form a ring of the formula:
  • R 6 , R 7 and a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 are substituents on R B .
  • the definition of each symbol is explained below.
  • X is O, S or NH and preferred is O,
  • Y is hydroxy, mercapto or amino and preferred is hydroxy
  • Z is O, S or NH and preferred is O,
  • C ring is N-containing aromatic heterocycle, wherein at least one atom neighboring to the atom at the bonding-position is N atom and preferred is optionally substituted pyridine-2-yl, optionally substituted pyrimidine-4-yl or optionally substituted 1,3,4-oxadiazole2-yl,
  • R B is a substituent selected from substitution group A and preferred is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle
  • R 1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle
  • Z 1 and Z 3 are each independently a bond, optionally substituted alkylene or optionally substituted alkenylene,
  • Z 2 is a bond, optionally substituted alkylene, optionally substituted alkenylene, —CH(OH)—, —S—, —SO—, —SO 2 —, —SO 2 NR 2 —, —NR 2 SO 2 —,—, —NR 2 —, —NR 2 CO—, —CON R 2 —, —C( ⁇ O)—O—, —O—C( ⁇ O)or —CO—,
  • R 2 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl or optionally substituted heteroaryl,
  • W 1 is —O or —N(—R G )-
  • R 3 to R 9 and R G are each independently a non-interfering substituent
  • R G is preferably hydrogen or alkyl.
  • R B examples include a substituent selected from substitution group A.
  • alkoxycarbonyl carboxy, alkyl, alkoxy, alkoxyalkyl, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, alkylcarbonyl, alkyl carbonyloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryl oxy, optionally substituted heteroaryl oxy, optionally substituted aryl thio, optionally substituted heteroaryl thio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyl oxy, optionally substituted a
  • alkyl More preferred are alkyl, hydroxy, alkoxy, optionally substituted amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.
  • alkyl hydroxy, alkoxy, optionally substituted amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.
  • R B of the above formula (III-1), (III-2), (VII-1), (VII-2), (VII-3), (VII-4), (VII-5), (VII-1), (IX-1), (X-1), (XI-1), (XII-1) and (XIII-1) includes optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroaryl alkyl, optionally substituted aryl oxy, optionally substituted heteroaryloxy, optionally substituted arylthio, optionally substituted heteroarylthio, optionally substituted aralkyloxy, optionally substituted heteroaryl alkyloxy, optionally substituted aralkylthio, optionally substituted heteroarylalkylthio, optionally substituted aryloxyalkyl, optionally substituted heteroaryloxyalkyl, optionally substituted hetero
  • optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle More preferred are optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl or optionally substituted heterocycle.
  • the ring formed by R C and R D , C ring and R B are optionally substituted with a non-interfering substituent(s).
  • the substituent may locate at one or more, preferably one to five, any substitutable positions.
  • the non-interfering substituent means any substituent not interfering with the integrase inhibitory activity.
  • the non-interfering substituent can be selected based on the determined integrase inhibitory activity and drug design using computer, as well as molecular weight, an der Waals' radius, electostatic characteristic of the substituent.
  • non-interfering substituent examples include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted
  • More preferred non-interfering substituents include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxy alkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthio alkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, nitroso, azide, amidino, guanidino, cyano, isocyano, mercapto, optionally substituted carbamoyl, sulfamoyl, sulfoamino, formyl, alkylcarbonyl, alkylcarbonyloxy, hydrazino, morpholino, optionally substituted ary
  • substituents include hydrogen, halogen, alkoxycarbonyl, carboxy, alkyl, alkoxy, alkoxyalkyl, nitro, hydroxy, alkenyl, alkynyl, alkylsulfonyl, optionally substituted amino, alkylthio, alkylthioalkyl, haloalkyl, haloalkoxy, haloalkoxyalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycle, oxo, thioxo, cyano, mercapto, optionally substituted carbamoyl, formyl, alkylcarbonyl, alkylcarbonyloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted optionally substituted heteroaryloxy,
  • non-interfering substituent on the ring formed by R C and R D are preferably hydrogen, halogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxycarbonylalkyl, heteroarylalkyl or hydroxy.
  • R 5 and R 5 ′ are each preferably hydrogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxycarbonylalkyl or heteroarylalkyl.
  • non-interfering substituent on C ring e.g., non-interfering substituent of R 3 , R 4 , R 8 , R 9 and R 1 ° are preferably halogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxycarbonylalkyl, heteroarylalkyl or hydroxy, and more preferred is hydrogen, alkyl, amino, halogen or hydroxy.
  • non-interfering substituent on R B are preferably halogen, alkyl, aralkyl, cycloalkyl, optionally substituted aryl, alkoxy, alkoxyalkyl, optionally substituted amino, hydroxy alkyl, alkenyl, alkoxycarbonylalkyl, heteroarylalkyl or hydroxy, and more preferred is hydrogen, alkyl, amino, halogen, hydroxy.
  • alkylene means C1 to C6 straight or branched chain alkylene, for example, methylene, ethylene, trimethylene, propylene, tetramethylene, ethylethylene, pentamethylene or haxamethylene.
  • C1 to C4 straight alkylene for example, methylene, ethylene, trimethylene or tetramethylene.
  • alkenylene is C2 to C6 straight or branched chain alkenylene derived from the above “alkylene” having one or more of double bond, for example, vinylene, propenylene or butenylene. Preferred is C2 to C3 straight alkenylene, for example, vinylene or propenylene.
  • alkyl means C1 to C10 straight or branched chain alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, n-decyl.
  • C1 to C6 alkyl for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl, isohexyl.
  • alkenyl means C2 to C8 straight or branched chain alkenyl derived from the above “alkyl” having one or more double, for example, vinyl, 1-propenyl, 2-propenyl,1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl.
  • aryl means monocyclic aromatic hydrocarbon group (e.g., phenyl) or polycyclic aromatic hydrocarbon group (e.g., 1-naphthyl, 2-naphthyl, 1-anthoryl,2-anthoryl,9-anthoryl,1-phenantryl, 2-phenantryl, 3-phenantryl, 4-phenantryl, 9-phenantryl).
  • phenyl or naphthyl e.g., 1-naphthyl, 2-naphthyl.
  • heteroaryl means monocyclic aromatic heterocyclic group and condensed aromatic heterocyclic group.
  • “monocyclic aromatic heterocyclic group” means 5- to 8-membered aromatic ring which may contain 1 to 4 of O, S and/or N atom and has a bonding radical at any substitutable position.
  • condensed aromatic heterocyclic group is a condensed ring formed by condensing a 5- to 8-membered aromatic ring which may contain 1 to 4 of O, S and/or N atom with a 1 to 4 of 5- to 8-membered aromatic carbocycle or the other 5- to 8-membered aromatic heterocycle, and the condensed ring has a bonding radical at any substitutable position.
  • heteroaryl examples include furyl (e.g., 2-furyl, 3-furyl), thienyl (e.g., 2-thienyl, 3-thienyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), triazolyl (e.g., 1,2,4-triazole-1-yl, 1,2,4-triazole-3-yl, 1,2,4-triazole-4-yl), tetrazolyl (e.g., 1-tetrazolyl, 2-tetrazolyl, 5-tetrazolyl), oxazolyl(e.g., 2-oxazolyl, 4-oxazolyl, 5-
  • cycloalkyl means C3 to C10 cyclic saturated hydrocarbon group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cycloctyl.
  • Preferred is C3 to C6 cycloalkyl, for example, cyclopentyl, cyclohexyl.
  • cycloalkenyl means C3 to C10 cyclic non-aromatic hydrocarbon group, for example, cyclopropenyl (e.g., 1-cyclopropenyl), cyclobutenyl (e.g., 1-cyclobutenyl), cyclopentenyl (e.g., 1-cyclopenten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl), cyclohexenyl (e.g., 1-cyclohexene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl), cycloheptenyl (e.g., 1-cycloheptenyl), cycloctenyl (e.g., 1-cycloctenyl).
  • Preferred is 1-cyclohexene-1-yl, 2-cyclohezene-1-yl, 3-cyclohezene-1-yl.
  • heterocycle means non-aromatic heterocyclic group which contains at least one of N, O, and S atom and has a bonding ragical at any substitutable position, for example, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, piperidino, 2-piperidino, 3-piperidil, 4-piperidil, 1-piperazinyl, 2-piperazinyl, 2-morpholinyl, 3-morpholinyl, morpholino, tetrahydropyranyl.
  • the “non-aromatic heterocyclic group” is saturated or unsaturated.
  • alkyl of “alkoxy” is the same as above “alkyl”, and “alkoxy” includes for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy. Preferred is methoxy, ethoxy.
  • alkoxycarbonyl means carbonyl substituted with the above “alkoxy”, including for example, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl.
  • alkoxyalkyl means the above “alkyl” substituted with the above “alkoxy”, including for example, methoxymethyl, ethoxymethyl, n-propoxymethyl, isopropoxymethyl, n-butoxymethyl, isobutoxymethyl, tert-butoxymethyl, methoxyethyl, ethoxyethyl, n-propoxyethyl, isopropoxyethyl, n-butoxyethyl, isobutoxyethyl, tert-butoxyethyl.
  • alkynyl means C2 to C8 alkynyl derived from the above “alkyl” having one or more of triple bond, including for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl.
  • alkylsulfonyl means sulfonyl substituted with the above “alkyl”, including for example, methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, n-pentylsulfonyl, isopentylsulfonyl, neopentylsulfonyl, tert-pentylsulfonyl, n-hexylsulfonyl, isohexylsulfonyl, n-heptylsulfonyl, n-octylsulfonyl, n-nonylsulf
  • substituent of “optionally substituted amino” and “optionally substituted carbamoyl” includes alkyl (e.g., methyl, ethyl, dimethyl), alkoxyalkyl (e.g., ethoxymethyl, ethoxyethyl), acyl (e.g., formyl, acetyl, benzoyl, toluoyl), aralkyl (e.g., benzyl, trityl), hydroxy.
  • alkyl e.g., methyl, ethyl, dimethyl
  • alkoxyalkyl e.g., ethoxymethyl, ethoxyethyl
  • acyl e.g., formyl, acetyl, benzoyl, toluoyl
  • aralkyl e.g., benzyl, trityl
  • alkylthio means sulfur atom substituted with the above “alkyl”, including for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio, n-pentylthio, isopentylthio, neopentylthio, tert-pentylthio, n-hexylthio, isohexylthio, n-heptylthio, n-octylthio, n-nonylthio, n-desylthio.
  • Preferred is sulfur atom substituted with C 1 to C6 alkyl.
  • alkylthioalkyl means the above “alkyl” substituted with the above “alkylthio”, including for example, methylthiomethyl, ethylthiomethyl, n-propylthiomethyl, isopropylthiomethyl, n-butylthiomethyl, isobutylthiomethyl, sec-butylthiomethyl, tert-butylthiomethyl, n-pentylthiomethyl, isopentylthiomethyl, neopentylthiomethyl, tert-pentylthiomethyl, n-hexylthiomethyl, isohexylthiomethyl, n-heptylthiomethyl, n-octylthiomethyl, n-nonylthiomethyl, n-desylthiomethyl, methylthioethyl, ethylthio ethyl, n-propylthioethyl, is
  • haloalkyl means the above “alkyl” substituted with one or more of halogen. Preferred is halogenated C1 to C3 alkyl, for example, trifluoromethyl, chloromethyl, dichloromethyl, 1,1-dichloroethyl, 2,2,2-tri chloro ethyl.
  • haloalkoxy means O substituted with the above “haloalkyl”, including for example, trifluoromethoxy, chloromethoxy, dichloromethoxy, 1,1-dichloro ethoxy, 2,2,2-trichloroethoxy.
  • haloalkoxyalkyl means the above “alkyl” substituted with the above “haloalkoxy”, including for example, trifluoromethoxymethyl, chloro methoxymethyl, dichloromethoxymethyl, 1,1-dichloroethoxymethyl, 2,2,2-trichloro ethoxymethyl, trifluoromethoxyethyl, chloromethoxyethyl, dichloromethoxyethyl, 1,1-dichloro ethoxyethyl, 2,2,2-trichloroethoxyethyl.
  • alkylcarbonyl means carbonyl substituted with the above “alkyl”, including for example, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaroyl, haxanoyl, octanoyl, lauroyl.
  • alkylcarbonyloxy means O substituted with the above “alkylcarbonyl”, including for example, acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, valeryloxy, isovaleryloxy, pivaroyloxy, haxanoyloxy, octanoyloxy, lauroyloxy.
  • aralkyl means the above “alkyl” substituted with 1 to 3 of the above “aryl”, including for example, benzyl, diphenylmethyl, triphenylmethyl, phenetyl,1-naphthyl methyl, 2-naphthylmethyl.
  • heteroarylalkyl means the above “alkyl” substituted with 1 to 3 of the above “heteroaryl”.
  • Preferred is heteroarylalkyl having C1 to C4 alkyl, esp., C1 or C2 alkyl, for example, furylmethyl, thienylmethyl, pyrrolylmethyl, imidazolyl methyl, pyrazolylmethyl, triazolylmethyl, tetrazolylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, thiadiazolylmethyl, isothiazolylmethyl, pyridyl methyl, pyridazinylmethyl, pirimidinylmethyl, furazanylmethyl, pyrazinylmethyl, ozadiazolylmethyl, benzofurylmethyl, benzothienylmethyl, benzimidazolyl methyl, dibenzofurylmethyl, benzoxazolylmethyl, quinoxalilmethyl
  • the substituent is selected from those which do not interfer with the integraseinhibitory activity, as well as tha case of above mentioned “non-interfering substituent”.
  • substituents include hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyl (e.g., CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl,
  • the substituent of “optionally substituted aryl”, “optionally substituted heteroaryl”, “optionally substituted cycloalkyl”, “optionally substituted cycloalkenyl”, and “optionally substituted heterocycle” is preferably hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyl (e.g., CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbon
  • the substituent of “optionally substituted alkylene” and “optionally substituted alkenylene” is preferably hydroxy, carboxy, halogen (e.g., F, Cl, Br, I), haloalkyl (e.g., CF 3 , CH 2 CF 3 , CH 2 CCl 3 ), alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy), alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl,
  • halogen e.g., F, Cl, Br, I
  • a non-interfering substituent is “optionally substituted aryl”, “optionally substituted heteroaryl”, “optionally substituted cycloalkyl”, “optionally substituted cycloalkenyl”, “optionally substituted heterocycle”, “optionally substituted aralkyl”, “optionally substituted heteroarylalkyl”, “optionally substituted aryloxy”, “optionally substituted heteroaryloxy”, “optionally substituted arylthio”, “optionally substituted heteroarylthio”, “optionally substituted aralkyloxy”, “optionally substituted heteroaryl alkyloxy”, “optionally substituted aralkylthio”, “optionally substituted heteroaryl alkylthio”, “optionally substituted aryl oxyalkyl”, “optionally substituted heteroaryl oxyalkyl”, “optionally substituted heteroaryl thioalkyl”, “optionally substituted heteroaryl thioalkyl”, “optionally substituted arylsulfonyl
  • the present invention includes the above mentioned compounds, prodrug, pharmaceutically acceptable salt and solvate thereof, as well as all tautomers and geometrical isomers.
  • keto/enol tautomers of the formula (I) are included in the present invention compounds.
  • the compounds of formula (XIII-1) and (XIII-2) may include the following tautomers:
  • a prodrug is a derivative of a compound of the present invention having a group which can be decomposed chemically or metabolically, and such a prodrug is converted to a pharmaceutically active compound of the present invention by means of solvolysis or by placing the compound in vivo under a physiological condition.
  • Method for the selection and process of an appropriate prodrug derivative are described in the literature such as Design of Prodrugs, Elsevier and Amsterdam 1985.
  • a prodrug of a compound of the present invention is preferably a lymph-directivity one.
  • the diseases caused by HIV include AIDS cerebrum symptom.
  • a preferable prodrug of a compound of the present invention is a brain-directivity one.
  • these lymph-directivity prodrug and brain-directivity prodrug the following prodrugs with high lipophilicity are preferable.
  • an ester derivative prepared by reacting a basal acid compound with a suitable alcohol or an amide derivative prepared by reacting a basal acid compound with a suitable amine is exemplified as a prodrug.
  • a especially preferred ester derivative as an prodrug is methylester, ethylester, n-propylester, isopropylester, n-butylester, isobutylester, tert-butylester, morpholinoethylester or N, N-diethylglycolamidoester.
  • an acyloxy derivative prepared by reacting a compound having a hydroxyl group with a suitable acylhalide or a suitable acid anhydride is exemplified as a prodrug.
  • a especially preferred acyloxy derivative as a prodrug is —O( ⁇ O)—CH 3 , —OC( ⁇ O)—C 2 H 5 , —OC( ⁇ O)-(tert-Bu), —OC( ⁇ O)—Cl 5 H 31 , —OC( ⁇ O)-(m-COONa-Ph), —OC( ⁇ O)—CH 2 CH 2 COONa, —O(C ⁇ O)—CH(NH 2 )CH 3 or —OC( ⁇ O)—CH 2 —N(CH 3 ) 2 .
  • an amide derivative prepared by reacting a compound having amino with a suitable acid halide or a suitable acid anhydride is exemplified as a prodrug.
  • a especially preferred amide derivative as a prodrug is —NHC( ⁇ O)—(CH 2 ) 20 CH 3 or —NHC( ⁇ O)—CH(NH 2 )CH 3 .
  • a prodrug can be produced by the chemical modification of Y.
  • Y is substituted with acyl and it is examined whether the prodrug is converted to a compound of the present invention by means of solvolysis or by placing the compound under a physiological condition or not. Therefore, even if Y is a substituent except for hydroxy, mercapto or amino, a compound converted to hydroxy, mercapto or amino by means of solvolysis or by placing the compound under a physiological condition is contained in prodrugs of the present invention and the present invention.
  • a compound converted to the present invention compound in phosphate buffer (pH7.4)-ethanol or plasma is a compound of the present invention.
  • salts of a compound of the present invention include, as basic salts, for example, alkali metal salts such as sodium or potassium salts; alkaline-earth metal salts such as calcium or magnesium salts; ammonium salts; aliphatic amine salts such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine or procaine salts; aralkyl amine salts such as N,N-dibenzylethylenediamine salts; heterocyclic aromatic amine salts such as pyridine salts, picoline salts, quinoline salts or isoquinoline salts; quaternary ammonium salts such as tetramethylammonium salts, tetraethylammonium salts, benzyltrimethylammonium salts, benzyltriethylammonium salts, benzyltributylammonium salts, methyltrio
  • Acid salts include, for example, mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate; organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts, malates, citrates salts, or ascorbates; sulfonates such as methanesulfonates, isethionates, benzenesulfonates, or p-toluenesulfonates; and acidic amino acid salts such as aspartates or glutamates.
  • mineral acid salts such as hydrochloride, sulfates salts, nitrate salts, phosphates salts, carbonates salts, hydrogencarbonates or perchlorate
  • organic acid salts such as acetates, propionates, lactates, maleates, fumarates, tararic acid salts,
  • solvates of a compound of the present invention for example, monosolvate, disolvate, monohydrate or dihydrate are also within the scope of the present invention.
  • inhibitor means that a compound of the present invention suppresses the action of integrase.
  • C ring, R 5 , Y, Z and the broken line are the same as above; L 1 and L 2 are leaving groups such as alkoxy; H a 1 is halogen; n is an integer of 0 or more, C ring may be substiuted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein Z 1 , Z 2 , Z 3 and R 1 are the same as above) and/or a non-interfering substituent.)
  • This process is for reacting compound of the formula (A1) with compound of the formula: R 5 NH 2 to give compound of the formula (B1).
  • Examples of compound of the formula (A1) include heteroarylalkyl halides.
  • R 5 NH 2 examples include alkylamine (e.g., methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, tert-butylamine, 2-ethylpropyl), cycloalkylamine (e.g., cyclohexylamine), arylamine (e.g., aniline), alkoxyamine (e.g., tert-butoxyamine), aralkylamine (e.g., benzylamine).
  • alkylamine e.g., methylamine, ethylamine, n-propylamine, isopropylamine, n-butylamine, tert-butylamine, 2-ethylpropyl
  • cycloalkylamine e.g., cyclohexylamine
  • arylamine e.g., aniline
  • alkoxyamine e.g., ter
  • solvent examples include dimethylformamide, alcohol (e.g., methanol, ethanol).
  • This process may be conducted in the presence of base (e.g. sodium hydrogencarbonate, potassium carbonate).
  • base e.g. sodium hydrogencarbonate, potassium carbonate.
  • This process is for reacting compound of the formula (B1) with compound of the formula: L 1 —C( ⁇ Y)—C( ⁇ Z)—L 2 in the presence of base to give compound of, the formula (I-A).
  • Examples of compound of the formula: L 1 —C( ⁇ Y)—C( ⁇ Z)—L 2 include oxalic acid dimethyl, oxalic acid diethyl.
  • Examples of base include metal alcolate (e.g. sodium methoxide, sodium ethoxide).
  • reaction solvent examples include alcohol (e.g., methanol, ethanol).
  • Compound (B1) can be prepared by the following process.
  • This process is for reacting compound of the formula (A2), in the presence of a reductant, with compound of the formula: R 5 NH 2 to give compound of the formula (B1).
  • Examples of compound of the formula (A2) include heteroarylalkyl.
  • Examples of compound of the formula: R 5 NH 2 include amine as used in Process A1.
  • reductant examples include NaBH 3 CN.
  • reaction solvent examples include alcohol (e.g., methanol, ethanol).
  • This process is for reacting compound of the formula (A3) with compound of the formula: R 5 NH 2 to give compound of the formula B2).
  • Examples of compound of the formula (A3) include vinyl pyrimidine (e.g., 4-vinyl-6-phenethylpyrimidine).
  • Examples of compound of the formula: R 5 NH 2 include amine as used in Process A 1.
  • reaction solvent examples include alcohol (e.g., methanol, ethanol).
  • This process is for condesing compound of the formula (C) with compound of the formula: R—C( ⁇ O)—NH—NH 2 to give compound of the formula (D).
  • Y is preferably protected in advance.
  • Examples of compound of the formula (C) include 2,5-dihydro-1-isopropyl-5-oxo-4-hydroxy-1H-pyrrole-3-carboxylic acid, and examples of its protected type include 2,5-dihydro-1-isopropyl-5-oxo-4-methoxy-1H-pyrrole-3-carboxylic acid.
  • Examples of compound of the formula: R—C( ⁇ O)—NH—NH 2 include acetyl hydrazine (e.g., phenylacetyl hydrazine, p-fuluorophenylacetyl hydrazine).
  • Examples of condensing agent include DCC (dicyclohexylcarbodiimide), WSCD (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), HOBt (1-hydroxybenzotriazole).
  • reaction solvent examples include tetrahydrofran, dimethylformamide.
  • This process is for halogenating compound of the formula (D), followed by treating with a base, to give compound of the formula (I-B).
  • Halogenation can be conducted by reacting compound of the formula (D) with bromine or the like in the presence of triphenylphosphine.
  • Examples of base include triethylamine.
  • reaction solvent examples include methylene chloride.
  • deprotection of Y can be conducted by reacting trimethylsilil chloride in the presence of NaI in acetonitrile.
  • R 5 , Y, Z, n, R B and H a 1 are the same as defined above.
  • R B is optionally substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 are the same as above) and/or a non-interfering substituent.)
  • This process is for reacting compound of the formula (E1) with compound of the formula: R 5 NH 2 to give compound of the formula (F1), according to Process A 1.
  • This process is for reacting compound of the formula (F1) with compound of the formula: L 1 —C( ⁇ Y)—C( ⁇ Z)—L 2 in the presence of a base to give compound of the formula (I-C), according to Process B.
  • This process is for reacting compound of the formula (E2) with compound of the formula: R 5 NH 2 to give compound of the formula (F), according to Process A 3.
  • This process is for reacting compound of the formula (G1) with compound of the formula: R 5 NH 2 to give compound of the formula (H1), according to Process E1
  • This process is for reacting compound of the formula (H1) with compound of the formula R B Li to give compound of the formula (H1).
  • the amino group in the formula (H1) is preferably protected in advance.
  • Examples of compound of the formula (H1) include 3-alkylamino propanic acid methylmethoxyamide (e.g., 3-methylamino propanic acid methylmethoxyamide, 3-ethyl amino propanic acid methylmethoxyamide, 3-n-propylamino propanic acid methylmethoxyamide, 3-n-butylamino propanic acid methylmethoxyamide, 3-ethyl propylamino propanic acid methylmethoxyamide, 3-tert-butylamino propanic acid methylmethoxyamide), 3-cycloalkyl amino propanic acid methylmethoxyamide (e.g., 3-cyclopropylaminopropanic acid methylmethoxyamide, 3-cyclopentylaminopropanic acid methylmethoxyamide, 3-cyclohexylaminopropanic acid methylmethoxyamide), 3-alkoxyaminopropaanic acid methylmethoxyamide (e.g., 3-(2-amin
  • R B Li examples include 5-(p-fluorobenzyl)fran-2-yllithium.
  • Compound of the formula: R B Li can be prepared by reacting compound of the formula: R B Br with butyl lithium.
  • This process is for reacting compound of the formula (J) with compound of the formula: L 1 —C( ⁇ Y)—C( ⁇ Z)—L 2 in the presence of a base to give compound of the formula (I-D), according to Process B and Process F.
  • This process is for reacting compound of the formula (G2) with compound of the formula: R 5 NH 2 to give compound of the formula (H2), according to Process A 3 and Process E 2.
  • This process is for reacting compound of the formula (K) with compound of the formula: R 5 NH 2 and compound of the formula: R 19 CHO to give compound of the formula (III), according to Zhurnal Orgarncheskoi Khimii, Vol. 22, No. 8, pp. 1749-1756.
  • Examples of compound of the formula (K) include that wherein, R B is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, or optionally substituted heterocycle, such as 2-hydroxy-4-oxo4-aryl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo4-heteroaryl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo4-cycloalkyl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo-4-cycloalkenyl-2-butenic acid alkyl ester, 2-hydroxy-4-oxo4-heterocycle-2-butenic acid alkyl ester wherein the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycle are substituted with a group of the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein,
  • Examples thereof include 4-(4-benzyloxybenzyl)-2-hydroxy-4-oxo-2-butenoic acid methylester, 4-[4-(4-fluorobenzyloxy)benzyl]-2-hydroxy-4-oxo-2-butenoic acid methylester, 4-(5-benzylfran-2-yl)-2-hydroxy-4-oxo-2-butenoic acid methylester, 4-[5-(4-fluorobenzyl)fran-2-yl]-2-hydroxy-4-oxo-2-butenoic acid methylester.
  • These compounds can be prepared according to the method described in WO0/39086.
  • R 5 NH 2 examples include alkylamine (e.g., methylamine, ethyl amine, n-propylamine, isopropylamine, n-butylamine, tert-butylamine, 2-ethyl propyl), cycloalkylamine (e.g., cyclohexylamine), arylamine (e.g., aniline), alkoxyamine (e.g., tert-butoxyamine), aralkylamine (e.g., benzylamine).
  • Compound of the formula: R 5 NH 2 may be used in an amount of 1 to 3 mol equivalent, preferably 1 to 2 mol equivalent per compound of the formula (K).
  • R 19 CHO examples include optionally substituted arylaldehyde(e.g., benzaldehyde), optionally substituted heteroaryl aldehyde(e.g., furfural), alkylaldehyde (e.g., acetoaldehyde), alkenylaldehyde, cycloalkyl aldehyde (e.g., cyclopropylaldehyde, cyclohexylaldehyde), formaldehyde and/or polymer thereof (formalin aqueous solution can be used.).
  • arylaldehyde e.g., benzaldehyde
  • heteroaryl aldehyde e.g., furfural
  • alkylaldehyde e.g., acetoaldehyde
  • alkenylaldehyde e.g., cycloalkyl aldehyde (e.g.,
  • R 19 CHO can be used in an amount of 1 to 3 mol equivalent, preferably 1 to 2 mol equivalent per compound of the formula (K).
  • Examples of leaving group include alkoxy.
  • the reaction temperature is O° C. to 100° C., preferably room temperature to 50° C., more preferably room temperature to 30° C.
  • reaction solvent examples include dioxane, ethanol, dimethylformamide, tetrahydrofran, acetonitrile, or a mixture thereof. Preferred is dioxane.
  • This process may be conducted in the presence of a base. This process is conducted for example as follows. To a solution or suspension of compound of the formula (K) in an organic solvent, were added compound of the formula: R 5 NH 2 and compound of the formula: R 19 CHO successiveively or simultaneously, and the mixture was stirred for several hours (preferably, 0.5 to 24 hours, more preferably 0.5 to 5 hour) at room temperature to 50° C. The reaction mixture was added to dil.
  • the present invention compound of the formula (III) can be readily prepared.
  • Compound of the formula: R 5 NH 2 or R 19 CHO can be synthesized or commrcially available.
  • This process can be conducted by the method used in the combinatorial chmistry (e.g., parallel synthesis). For example, to each well of a plate with 96 holes, are added an organic solvent (e.g., dioxane), compound of the formula (K), compound of the formula: R 5 NH 2 and compound of the formula: R 19 CHO, which is shaken at room temperature to 50° C., then evaporated to remove the organic solvent to give a library of compounds of the formula (III). In this process, generation of by-products can be controled at low level, thus the evaporation of the used organic solvent readily give an sample for the bioassay.
  • organic solvent e.g., dioxane
  • K compound of the formula: R 5 NH 2
  • R 19 CHO compound of the formula: R 19
  • the library of the present invention compound can consists of 2 or more compounds obtained by the above method.
  • the library means a group consisting of 2 or more compounds having a commomn partial structure.
  • Examples of the commomn partial structure include a pyrrolinone structure.
  • the pyrrolinone structure is preferably substituted with hydroxy and a group of the formula: —C( ⁇ O)—R B —Z 1 —Z 2 —Z 3 —R 1 .
  • a compound having such a commomn partial structure possesses an HIV integrase inhibitory activity and a library consisting of such compounds is useful for screening an anti-HIV agent, AIDS-treating agent etc., as well as other medicines.
  • the library is a group preferably consisting of 10 or more compounds, more preferably 50 or more.
  • the library of the present invention comprises at least one compound of the present invention.
  • a compound included in the library is very useful for screening a compound possessing a potent HIV integrase inhibitory activity.
  • a preferable starting material is of the formula (K):
  • a more preferable starting material of the formula (K) is a compound wherein X is O; Y is hydroxy; Z is O; R B is heteroaryl; R B is not substituted with R 1 and R 7 Lis alkoxy; Z 1 and Z 3 are bonds; Z 2 is methylene; R 1 is 4-fluorophenyl. Further preferred is 4-[5-(4-fluorobenzyl)fran-2-yl]-2-hydroxy-4-oxo2-butenoic acid alkyl ester.
  • R 5 NH 2 or R 19 CHO can be selected from commercially available amine and aldehyde with reference to molecular weight thereof.
  • Compound of the formula: R 1 NH 2 can-be selected from amine shown below:
  • R 19 CHO can be selected from aldehyde shown below. formaldehyde, ethyl 2-formyl-1-cyclopropancarboxylate, cyclohexancarboaldehyde, 1,2,3,6-tetrahydrobenzaldehyde, 1-methylpyrrole-2-carboaldehyde, furfural, 5-nitro-2-fulaldehyde, 5-methylfurfural, 5-hydroxymethyl-2-fulaldehyde, 3-(2-furyl)acrolein, benzaldehyde, 2-fluorobenzaldehyde, 2-chlorobenzaldehyde, o-anisealdehyde, salicylaldehyde, 3-fluoro-2-hydroxybenzaldehyde, 2,3-dihydroxybenzaldehyde, 2,5-dihydroxybenzaldehyde, o-naphthalaldehyde, o-tolalde
  • This process is for reacting compound of the formula (L) with hydrogen peroxide in the presence of a base to give compound of the formula (1-F).
  • Examples of compound of the formula (L) include 4-(benzyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluorobenzyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(phenetyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluoro phenetyloxy)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(phenetyl)-2-(1-oxo-3-(2-pyridyl)-2-propenyl)phenol, 4-(p-fluorophenetyl)-2-(1-oxo-3-(2-pyridyl)-2-propennyl)phenol.
  • Examples of base include 2N NaOH aq. solution.
  • Examples of hydrogen peroxide include 30% hydrogen peroxide.
  • reaction solvent examples include alcohol (e.g., methanol, ethanol).
  • This process is for reacting compound of the formula (M) with a base to give compound of the formula (I-F).
  • Y is preferably protected in advance.
  • Examples of compound of the formula (M) include 2-(2-benzoyloxyl-oxoethyl)-3-methoxyphenyl-2-picolilate.
  • Examples of base include NaH.
  • solvent examples include dimethylformamide.
  • This process is for reacting compound of the formula (N) with compound of the formula: R—C( ⁇ O)—NH—NH 2 in the presence of a condensing agent to give compound of the formula (O).
  • Y and/or Z is preferably protected in advance.
  • the process may be conducted as well as Process C.
  • Examples of compound of the formula (N) include 3-hydroxy-4-oxo-1H-quinoline-2-carboxylic acid, 3-hydroxy-4-oxo-1-methyl-1H-quinoline-2-carboxylic acid, 3-hydroxy-4-oxo-4H-chromene-2-carboxylic acid.
  • Examples of its protected type include 2-ethoxycarbonyl-3-methoxy-1H-quinoline-4-one, 2-ethoxycarbonyl-3-methoxy-1-methyl-1H-quinoline-4-one, 3-benzyloxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester, 3-methoxy-4-oxo-4H-chromene-2-carboxylic acid ethyl ester.
  • These compounds can be prepared according to the method of J.Heterocyclic Chem, 24, p1649, 1987.
  • This process is for preparing compound of the formula (I-G) from compound of the formula (0).
  • the process, oxadiazole ring formation from diacylhydrazine, can be conducted by heating diacylhydrazine together with phosphorus oxychloride or thionyl chloride.
  • the reaction temperature is 50 to 100° C., preferably 80 to 100° C.
  • the process can also be conducted in the presence of triethylamine dibromotri phenylphospholan.
  • the reaction temperature is 0 to 100° C., preferably 0 to 30° C.
  • the reaction solvents include dichloromethane and tetrahydrofran.
  • This process is for halogenating compound of the formula (N), followed by treating with a base, to give compound of the formula (I-G), as well as Process O.
  • This process is for reacting compound of the formula (P) with compound of the formula: R—C( ⁇ O)—OH in the presence of a condensing agent to to give compound of the formula (O).
  • Y and Z are preferably protected in advance.
  • the process can be conducted as well as Process C and Process N.
  • Examples of compound of the formula (P) include 2-hydrazinocarbonyl-3,4-dihydroxyquinoline. Protected types thereof include 2-hydrazinocarbonyl-3,4-dimethoxyquinoline.
  • R 6 , R 7 , R B , R E , R F , X and Y are the same as above; L is a leaving group; Q is a protecting group; Y A is O, S or NH 2 ; R X is the formula: —Z 1 —Z 2 —Z 3 —R 1 (wherein, Z 1 , Z 2 , Z 3 and R 1 are the same as above))
  • This process is for reacting compound of the formula (Q-1) with compound of the formula (Q-2) to give compound of the formula (Q-3).
  • Examples of compound of the formula (Q-1) include cyclohexenon which can be prepared by the known method (Tetrahedron, 1997, 53, p8963).
  • Examples of compound of the formula (Q-2) include furan-2-carboxylic acid halides which can be prepared by the known method (Zhurnal Organicheskoi Khimii, Vol. 22, No. 8, pp. 1749-1756).
  • reaction solvent examples include aethers (e.g., tetrahydrofran, dioxane) and N,N-dimethylformamide, which can be used by itself or in combination.
  • the process can be conducted in the presence of a base (e.g., lithium bistri methylsililamide) or an acid (e.g., ZnCl 2 , TiCl 4 , HCl).
  • a base e.g., lithium bistri methylsililamide
  • an acid e.g., ZnCl 2 , TiCl 4 , HCl
  • Examples of acid include hydrochloric acid and sulfuric acid.
  • reaction solvent examples include aethers (e.g., tetrahydrofran, dioxane), alcohols (e.g., methanol, ethanol), which can be used by itself or in combination.
  • aethers e.g., tetrahydrofran, dioxane
  • alcohols e.g., methanol, ethanol
  • This process is for reacting compound of the formula (S-1) with compound of the formula (S-2) to give compound of the formula (S-3).
  • Examples of compound of the formula (S-1) include pyridine carboxylic acid which can be prepared from picoline by oxidation with selenium dioxide and esterfication.
  • Examples of compound of the formula (S-2) include protected 2-hydroxyacetic acid esters.
  • reaction solvent examples include aether (e.g., tetrahydrofran, dioxane), N,N-dimethylformamide, which can be used by itself or in combination.
  • aether e.g., tetrahydrofran, dioxane
  • N,N-dimethylformamide which can be used by itself or in combination.
  • the process can be conducted in the presence of a base (e.g., lithium bistri methylsililamide).
  • a base e.g., lithium bistri methylsililamide
  • This process is for reacting compound the formula (S-3) with compound of the formula (T-1) to give compound of the formula (T-2).
  • Examples of compound of the formula (T-1) include amidines.
  • reaction solvent examples include alcohol (e.g., methanol, ethanol).
  • the process can be conducted in the presence of a base (e.g., sodium methoxide).
  • a base e.g., sodium methoxide
  • reaction solvent examples include alcohol (e.g., methanol, ethanol), aether (e.g., tetrahydrofran, dioxane), which can be used by itself or in combination.
  • alcohol e.g., methanol, ethanol
  • aether e.g., tetrahydrofran, dioxane
  • the process can be conducted in the presence of an acid (e.g., hydrochloric acid, p-toluene sulfonic acid) or by adding hydrogen.
  • an acid e.g., hydrochloric acid, p-toluene sulfonic acid
  • hydrogen e.g., hydrochloric acid, p-toluene sulfonic acid
  • This process is for reacting compound of the formula (U-1) with a sulfurizing reagent or an amine to give compound of the formula (V-1).
  • sulfurizing reagent examples include Lawson's reagent and phosphorus pentasulfide.
  • Examples of amine include methylamine and morpholine.
  • reaction solvent examples include aromatichydrocarbon (e.g., toluene, xylene), aether (e.g., tetrahydrofran, dioxane) which can be used by itself or in combination.
  • aromatichydrocarbon e.g., toluene, xylene
  • aether e.g., tetrahydrofran, dioxane
  • This process is for reacting compound of the formula (W-1) with compound of the formula (W-2) to give compound of the formula (W-3).
  • Examples of compound of the formula (W-1) include pyrazolones.
  • Examples of compound of the formula (W-2) include those exemplified as compound of the formula (Q-2).
  • reaction solvent examples include aether (e.g., tetrahydrofran, dioxane), N,N-dimethylformamide, which can be used by itself or in combination.
  • aether e.g., tetrahydrofran, dioxane
  • N,N-dimethylformamide which can be used by itself or in combination.
  • the process can be conducted in the presence of a base (e.g., n-butyllithium).
  • a base e.g., n-butyllithium
  • reaction solvent examples include alcohol (e.g., methanol, ethanol), aether (e.g., tetrahydrofran, dioxane), which can be used by itself or in combination.
  • alcohol e.g., methanol, ethanol
  • aether e.g., tetrahydrofran, dioxane
  • the process can be conducted in the presence of an acid (e.g., hydrochloric acid,-toluenesulfonic acid or by adding hydrogen.
  • an acid e.g., hydrochloric acid,-toluenesulfonic acid or by adding hydrogen.
  • the present invention compounds can also be prepared according to the general oraganic synthesis method of heterocyclyl compounds descrived in literatures e.g., (1) Alan R. Katriszly et al., Comprehensive Heterocyclic Chemistry, (2) Alan R.Katriszly et al., Comprehensive Heterocyclic Chemistry 11, (3) RODD'S CHEMISTRY OF CARBON COMPOUNDS VOLUME IV HETEROCYCLIC COMPOUNDS.
  • This process is for reacting compound of the formula (AA-1) with compound of the formula (AA-2) in the presence of a base to give compound of the formula (AA-3).
  • Examples of compound of the formula (AA-1) include Boc-protected pyrrolidine 2-one which can be prepared by the known method (Tetrahedron Lett., 36, 8949-8952 (1995)).
  • This process is for cyclizing compound of the formula (AA-3), optionally followed by Retroclaisen Reaction, to give compound of the formula (AB).
  • the cyclization can be conducted as well as Process B.
  • Retroclaisen Reaction can be conducted by treating with a base such as LiOH in a solvent such as tetrahydrofran.
  • This process is for reacting compound of the formula (AB) with compound of the formula: R 5 -L (wherein L is a leaving group) in the presence of a base to give compound of the formula (AC).
  • the process can be conducted according to the conventional N-alkylation.
  • compound of the formula (AB) is reacted with bromoethane etc. in the presence of a base such as potassium bis(trimethylsilil)amide in a solvent such as tetrahydrofran.
  • This process is for dehydrating compound of the formula (BA-1) to give compound of the formula (BA-2).
  • Examples of compound of the formula (BA-1) include 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylic acid ethyl ester, which can be prepared by the known method (Org. Prep. Proced. Int., 29, 330-335 (1997)).
  • the process can be conducted by treating compound of the formula (BA-1) with a catalytic amount of paradium carbon in a solvent such as oxylene.
  • This process is for protecting a reactive substituent of compound of the formula (BA-2) to give compound of the formula (BB).
  • Examples of a protecting group include alkyl and alkoxyalkyl, which can be introduced by the conventional protection reaction (Protective Groups in Organic Synthesis, Theodora W. Greene).
  • This process is for converting compound of the formula (BB) into compound of the formula (BC), according to the method of Process H and Process AA.
  • This process is for reacting compound of the formula (BB) with hydrazine to give compound of the formula (CA).
  • the process can be conducted by reaction with hydrazine in a solvent such as ethanol.
  • This process is for converting compound of the formula (CA) into compound of the formula (CB) according to the methods of Process N and Process P.
  • This process is for converting compound of the formula (CB) into compound of the formula (CC) according to the method of Process M.
  • This process is for deprotecting compounds of the formula (CC) and (CD) according to the method of Process CD and CE.
  • Examples of compound of the formula (DA-1) include 3-hydroxy-4-methoxypyridine-2-carboxylic acid which can be obtained by the known method (Tetrahedron, 54, 12745-12774 (1998)). The esterification can be conducted by the conventional method.
  • This process is for protecting a reactive substituent of compound of the formula (DA-2) to give compound of the formula (DB).
  • the protecting group is preferably alkyl.
  • the protection can be conducted according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).
  • This process is for converting compound of the formula (DB) into compound of the formula (DC) according to Process BC.
  • This process is for deprotecting compound of the formula (DC) to give compound of the formula (DD), according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).
  • This process is for halogenating compound of the formula (EA-1) to give compound of the formula (EA-2).
  • Examples of compound of the formula (EA-1) include 5-methoxy-6-methyl-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid methyl ester which can be obtained by the known method (WO92/02523).
  • the halogenation can be conventionally conducted, for example, compound of the formula (EA-1) is heated in phosphorus oxychloride.
  • This process is for substituting halogen of compound of the formula (EA-2) with a group of Y A Q to give compound of the formula (EB).
  • Compound of the formula (EA-2) is reacted with sodium methoxide in a solvent such as methanol.
  • This process is for substituting OR N1 of compound of the formula (EB) with a leaving group L to give compound of the formula (EC).
  • This process is for converting compound of the formula (EC) into compound of the formula (ED) according to Process BC.
  • This process is for deprotecting compound of the formula (ED) to give compound of the formula (EF) according to the conventional method (Protective Groups in Organic Synthesis, Theodora W. Greene).
  • the present invention compound is useful for preparing a pharmaceutical composition such as antivirus agent.
  • the present invention compound possessing a remarkable inhibitory activity on integrase of virus, is expected to exhibit a preventing or treating effect for diseases caused by viruses which grow at least via production of integrase in infected animal cells, thus being useful as an integrase inhibitor against a retro-virus (e.g., HIV-1, HIV-2, HTLV-1, SIV, FIV) as well as an anti-HIV agent.
  • a retro-virus e.g., HIV-1, HIV-2, HTLV-1, SIV, FIV
  • the present invention compound can be used in combination with other anti-HIV agents having a different action of mechanisum such as a reverse transcriptase inhibitor and/or a protease inhibitor. Since any of the integrase inhibitors have not been on sale, a combination therapy of the present invention compound with a reverse transcriptase inhibitor and/or a protease inhibitor is very useful.
  • the present invention compound can be used as a combind agent for enhansing the anti-HIV acitivity of other HIV agents, as shown in the cocktail therapy.
  • the present invention compound can be used in gene therapy in order to prevent a retrovirus vector derived from HIV or MLV from spreading over non-targetd tissues.
  • administration of the present invention compound in advanc can prevent an unnecessary infection in the body.
  • the compounds of the present invention can be administered orally or parenterally.
  • the compounds of the present invention can be used in any form of usual formulations, for example, solid formulations such as tablets, powders, granules, capsules; aqueous formulations; oleaginous suspensions; solutions such as syrup or elixir.
  • the compounds of the present invention can be used as an aqueous or oleaginous suspension injection, or nose drops.
  • conventional excipients, binding agents, lubricants, aqueous solvents, oleaginous solvents, emulsifying agents, suspending agents, preservatives, stabilizers, and the like can be optionally used.
  • Preferred is an oral agent as an HIV-agent.
  • a formulation according to the present invention may be manufactured by combining (for example, admixing) a curatively effective amount of a compound of the present invention with a pharmaceutically acceptable carrier or diluent.
  • the formulation of the present invention may be manufactured with well-known and easily available ingredients in accordance with a known method.
  • an active ingredient is admixed or diluted with a carrier, or they are contained in a carrier in the form of capsule, sacheier, paper, or another container.
  • the carrier is a solid, semi-solid, or liquid material which functions as a medium.
  • a formulation according to the present invention may be produced in the form of tablet, pill, powder medicine, intraoral medicine, elixir agent, suspending agent, emulsifier, dissolving agent, syrup agent, aerosol agent (solid in liquid medium), and ointment.
  • Such a formulation may contain up to 10% of an active compound. It is preferred to formulate a compound of the present invention prior to administration.
  • a carrier is in the form of solid, liquid, or a mixture of solid and liquid.
  • a compound of the present invention is dissolved into 4% dextrose/0.5% sodium citrate aqueous solution so as to be 2 mg/ml concentration for intravenous injection.
  • Solid formulation includes powder, tablet, and capsule.
  • Solid carrier consists of one or more of material(s) for serving also as fragrant, lubricant, dissolving agent, suspension, binder, tablet disintegrator, capsule.
  • a tablet for oral administration contains a suitable excipient such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and the like together with a disintegrator such as corn starch, alginic acid and the like and/or a binder such as gelatin, acacia and the like, and a lubricant such as magnesium stearate, stearic acid, talc and the like.
  • a suitable excipient such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and the like together with a disintegrator such as corn starch, alginic acid and the like and/or a binder such as gelatin, acacia and the like, and a lubricant such as magnesium stearate, stearic acid, talc and the like.
  • a carrier is a finely pulverized solid which is blended with finely pulverized active ingredients.
  • active ingredients are admixed with a carrier having required binding power in a suitable ratio, and it is solidified in a desired shape and size.
  • Powder medicine and tablet contain about 1 to about 99% by weight of the active ingredients being novel compounds according to the present invention.
  • suitable solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth gum, methyl cellulose, sodium carboxymethylcellulose, low-melting wax, and cocoa butter.
  • a liquid formulation includes suspending agent, emulsifier, syrup agent, and elixir agent.
  • Active ingredients may be dissolved or suspended into a pharmaceutically acceptable carrier such as sterile water, a sterile organic solvent, a mixture thereof and the like. Active ingredients may be dissolved frequently into a suitable organic solvent such as propylene glycol aqueous solution. When finely pulverized active ingredients are dispersed into aqueous starch, sodium carboxylmethylcellulose solution, or suitable oil, the other compositions can be prepared.
  • an appropriate dosage of the compound of the present invention varies depending on the administration route, age, body weight, conditions of the patient, and kind of disease
  • the daily dosage in the case of oral administration, can be between approximately 0.05-3000 mg, preferably approximately 0.1-1000 mg, for an adult.
  • the daily dosage can be administered in divisions.
  • the daily dosage for an adult in the case of parenteral administration, can be between approximately 0.01-1000 mg, preferably approximately 0.05-500 mg.
  • reactions are usually carried out under nitrogen atmosphere, and reaction solvents are used as dried over molecular sieve and the like. Extracts are dried over sodium sulfate or magnesium sulfate and the like.
  • the solution was allowed to stand overnight at room temperature. The mixture was evaporated under reduced pressure, to which were added ethyl acetate(500 ml), 2N hydrochloric acid(70 ml)and water(300 ml) and the solution was shaken and separated. The solution was washed with water(200 ml), a saturated sodium bicarbonate aqueous solution(100 ml)and water(100 ml), and water(200 ml) successively.
  • the reaction mixture was poured into an ice water, to which were added ethyl acetate(800 ml) and 2N hydrochloric acid(600 ml) and extracted. The water solution was reextracted with ethyl acetate(400 ml). The ethyl acetate solution was washed one time with water(600 ml), dried with magnesium sulfate and evaporated under reduced pressure.
  • N-hexane and diethyl ether(2:1, 720 ml) were added to a crystal residue(130.7 g), to give crude crystal(71.15 g, 78.7%) of A-21 which was recrystallized from dichloromethane and n-hexane to give A-21(47.82 g, yield:52.9%).
  • the water layer was alkalinized with 2N sodium hydroxide aqueous solution(100 ml) and extracted with toluene.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US10/485,394 2001-08-10 2002-08-08 Antiviral agent Abandoned US20040229909A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/603,979 US9572813B2 (en) 2001-08-10 2015-01-23 Antiviral agent
US15/356,343 US20170066754A1 (en) 2001-08-10 2016-11-18 Antiviral agent

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001245071 2001-08-10
JP2001-245071 2001-08-10
JP2001-370860 2001-12-05
JP2001370860 2001-12-05
JP2002191483 2002-06-28
JP2002-191483 2002-06-28
PCT/JP2002/008108 WO2003016275A1 (en) 2001-08-10 2002-08-08 Antiviral agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008108 A-371-Of-International WO2003016275A1 (en) 2001-08-10 2002-08-08 Antiviral agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/603,979 Continuation US9572813B2 (en) 2001-08-10 2015-01-23 Antiviral agent

Publications (1)

Publication Number Publication Date
US20040229909A1 true US20040229909A1 (en) 2004-11-18

Family

ID=27347328

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/485,394 Abandoned US20040229909A1 (en) 2001-08-10 2002-08-08 Antiviral agent
US14/603,979 Expired - Fee Related US9572813B2 (en) 2001-08-10 2015-01-23 Antiviral agent
US15/356,343 Abandoned US20170066754A1 (en) 2001-08-10 2016-11-18 Antiviral agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/603,979 Expired - Fee Related US9572813B2 (en) 2001-08-10 2015-01-23 Antiviral agent
US15/356,343 Abandoned US20170066754A1 (en) 2001-08-10 2016-11-18 Antiviral agent

Country Status (16)

Country Link
US (3) US20040229909A1 (enrdf_load_stackoverflow)
EP (4) EP1422218B1 (enrdf_load_stackoverflow)
JP (3) JP4338192B2 (enrdf_load_stackoverflow)
KR (2) KR20100087209A (enrdf_load_stackoverflow)
CN (2) CN100491349C (enrdf_load_stackoverflow)
AT (2) ATE530520T1 (enrdf_load_stackoverflow)
BR (1) BR0211750A (enrdf_load_stackoverflow)
CA (1) CA2452769C (enrdf_load_stackoverflow)
CY (2) CY20162200001T2 (enrdf_load_stackoverflow)
DE (2) DE15187654T1 (enrdf_load_stackoverflow)
DK (2) DK2266958T1 (enrdf_load_stackoverflow)
ES (3) ES2383262T3 (enrdf_load_stackoverflow)
MX (1) MXPA04000646A (enrdf_load_stackoverflow)
PT (1) PT2266958T (enrdf_load_stackoverflow)
TW (1) TWI327137B (enrdf_load_stackoverflow)
WO (1) WO2003016275A1 (enrdf_load_stackoverflow)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US20050025774A1 (en) * 2001-10-26 2005-02-03 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US20050075356A1 (en) * 2001-10-26 2005-04-07 Di Francesco Maria E. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US20050261322A1 (en) * 2004-05-18 2005-11-24 Naidu B N HIV integrase inhibitors
US20060046985A1 (en) * 2002-12-27 2006-03-02 Benedetta Crescenzi Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors
US20070155744A1 (en) * 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US20070179196A1 (en) * 2004-03-09 2007-08-02 Wei Han Hiv integrase inhibitors
US20070249687A1 (en) * 2004-09-15 2007-10-25 Hiroshi Yoshida Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase
US20080015187A1 (en) * 2004-06-09 2008-01-17 Wai John S Hiv Integrase Inhibitors
US20080139579A1 (en) * 2004-03-09 2008-06-12 Merck & Co., Inc. Hiv Integrase Inhibitors
US20080161271A1 (en) * 2005-02-21 2008-07-03 Hiroshi Yoshida Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
US20080287394A1 (en) * 2004-05-07 2008-11-20 Merck & Co., Inc. Hiv Integrase Inhibitors
US20090054399A1 (en) * 2005-05-10 2009-02-26 Vacca Joseph P Hiv integrase inhibitors
US20090221571A1 (en) * 2005-10-04 2009-09-03 Vincenzo Summa Hiv integrase inhibitors
WO2010000031A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones and uses thereof
WO2010000032A1 (en) 2008-07-02 2010-01-07 Avexa Limited Compounds having antiviral properties
WO2010000030A1 (en) 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
US20100087419A1 (en) * 2008-10-06 2010-04-08 Isaacs Richard C A Hiv integrase inhibitors
US7745453B2 (en) 2003-12-22 2010-06-29 Shionogi & Co., Ltd. Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase
US20100216834A1 (en) * 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
US7820680B2 (en) 2004-03-09 2010-10-26 Merck & Co., Inc. HIV integrase inhibitors
US20110130397A1 (en) * 2006-09-22 2011-06-02 Soongyu Choi Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
US7981879B2 (en) 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2015048363A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015117094A1 (en) * 2014-02-03 2015-08-06 American Life Science Pharmaceuticals, Inc. Compositions and methods for synthesizing (2s,3s)-trans-epoxysuccinyl-l-leucyl-amido-3-methylbutane ethyl ester
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2016191239A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US9572813B2 (en) 2001-08-10 2017-02-21 Shionogi & Co., Ltd. Antiviral agent
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017116928A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
CN107773562A (zh) * 2016-08-25 2018-03-09 清华大学 化合物在抗登革和寨卡病毒感染中的应用
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018102485A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US10065930B2 (en) 2014-08-06 2018-09-04 Eisai R&D Management Co., Ltd. Method for producing pyrimidine-1-ol compound, and intermediate thereof
CN110431224A (zh) * 2017-03-13 2019-11-08 帝斯曼知识产权资产管理有限公司 锌双核簇转录调控因子缺陷型菌株

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2004062613A2 (en) 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP4607469B2 (ja) * 2003-01-29 2011-01-05 三洋化成工業株式会社 ウレタン樹脂及びその粉体の製造方法
AU2004212421B2 (en) * 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
EA014162B1 (ru) 2005-04-28 2010-10-29 Смитклайн Бичем Корпорейшн Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич
JP2006342115A (ja) * 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
EP1950212B1 (en) 2005-10-27 2016-02-24 Shionogi Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
WO2007054105A2 (en) * 2005-11-14 2007-05-18 H. Lundbeck A/S Method for the preparation of escitalopram
EP2557080A1 (en) 2006-04-04 2013-02-13 The Regents of The University of California Method for identifying pI3-kinase antagonists
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
US20100041653A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
JP2012532849A (ja) * 2009-07-10 2012-12-20 ビバリス Ｃ型肝炎ｎｓ５ｂポリメラーゼの阻害剤としての１−（６員アゾ複素環式）−ピロリン−２−オン化合物、その医薬組成物、およびそれらの治療上の使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CN101967209B (zh) * 2010-10-20 2012-11-07 南京大学 一种n-乙酰基乙二胺螯合树脂及其制备方法
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
UA108713C2 (xx) 2011-11-11 2015-05-25 2-тіопіримідинони
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6183053B2 (ja) * 2012-08-22 2017-08-23 宇部興産株式会社 テトラヒドロピラニルピリミジン化合物の製造方法
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California IRE1 MODULATION
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TWI642669B (zh) 2012-12-21 2018-12-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103172581A (zh) * 2013-04-07 2013-06-26 杨国成 一种5-氨基-3-巯基-1,2,4-三氮唑晶体及其制备方法
GB201308217D0 (en) 2013-05-08 2013-06-12 Ucl Business Plc Compounds and their use in therapy
CN104148018B (zh) * 2013-05-14 2018-04-20 上海亨臻实业有限公司 抗体亲和纯化材料及其用途
NO2865735T3 (enrdf_load_stackoverflow) 2013-07-12 2018-07-21
SI3252058T1 (sl) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102365651B1 (ko) 2013-10-04 2022-02-21 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (enrdf_load_stackoverflow) 2014-06-20 2018-06-23
US10011613B2 (en) 2014-08-22 2018-07-03 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
WO2016178113A1 (en) 2015-05-05 2016-11-10 Pfizer Inc. 2-thiopyrimidinones
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN105237406A (zh) * 2015-10-14 2016-01-13 湖南华腾制药有限公司 (r)-(-)-1-甲基-3-苯丙胺的合成方法
US10414735B2 (en) 2015-11-09 2019-09-17 Forge Therapeutics, Inc. Substituted hydroxypyrimidinones for treating bacterial infections
US10611747B2 (en) 2015-11-09 2020-04-07 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
ES2881776T3 (es) * 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN106810458B (zh) * 2016-12-31 2019-05-03 武汉工程大学 一种拆分dl-2-氨基丙醇制备l-2-氨基丙醇的方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
WO2018208985A2 (en) * 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
CN111094255B (zh) 2017-09-14 2023-10-03 第一三共株式会社 具有环状结构的化合物
LT3759113T (lt) 2018-02-28 2024-11-11 Novartis Ag 10-(di(fenil)metil)-4-hidroksi-8,9,9a,10-tetrahidro-7h-pirolo[1',2':4,5] pirazino[1,2-b]piridazin-3,5-diono dariniai ir susiję junginiai kaip ortomiksoviruso replikacijos inhibitoriai, skirti gripo gydymui
CN108658784B (zh) * 2018-04-26 2020-12-18 联化科技股份有限公司 (r)-1-(4-甲基苯基)乙胺的合成方法
JP7495395B2 (ja) 2018-09-20 2024-06-04 ブラックスミス メディシンズ，インク． 抗菌性化合物
CN112867714B (zh) 2018-10-23 2024-06-11 巴斯夫欧洲公司 杀害虫的三环化合物
WO2020132820A1 (zh) * 2018-12-24 2020-07-02 广东莱佛士制药技术有限公司 一种3-(苄氧基)-4-氧代-4h-吡喃-2-羧酸的合成方法
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
CN110563943A (zh) * 2019-09-09 2019-12-13 中国科学院长春应用化学研究所 一种生物基聚合物及其制备方法
US11731962B2 (en) 2020-03-25 2023-08-22 Blacksmith Medicines, Inc. LpxC inhibitor and methods of making
AU2021256876A1 (en) 2020-04-14 2022-11-03 Basf Se Tricyclic pesticidal compounds
EP4153578A1 (en) * 2020-05-18 2023-03-29 Salk Institute for Biological Studies Chromen-4-one derivatives, such as e.g. flavones, for use as ck2 inhibitors for the treatment of neuroinflammation
MX2023003273A (es) 2020-09-21 2023-04-26 Landos Biopharma Inc Ligandos de nlrx1.
CA3233328A1 (en) 2021-09-28 2023-04-06 Min Teng Lpxc inhibitors and uses thereof
WO2023243678A1 (ja) 2022-06-15 2023-12-21 日産化学株式会社 ピラゾール化合物、その製造中間体、及び有害生物防除剤
WO2025085347A1 (en) * 2023-10-19 2025-04-24 Merck Sharp & Dohme Llc Il4i1 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039060A1 (en) * 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US20050025774A1 (en) * 2001-10-26 2005-02-03 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7745453B2 (en) * 2003-12-22 2010-06-29 Shionogi & Co., Ltd. Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3244725A (en) 1964-09-21 1966-04-05 Taub William 4, 5-diacyl-3-hydroxy-3-pyrrolin-2-ones
US4298743A (en) * 1979-09-11 1981-11-03 Merck & Co., Inc. 4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
DE3820176A1 (de) 1987-12-18 1989-06-29 Bayer Ag Verfahren zur herstellung von phosphorsaeurederivaten und zwischenprodukten
WO1992002523A1 (en) 1990-08-02 1992-02-20 Sankei Pharmaceutical Company Limited Novel cephalosporin compound
WO1992006954A2 (en) 1990-10-15 1992-04-30 Pfizer Inc. Pyrrolidine dione derivatives
JPH06100445A (ja) * 1992-07-06 1994-04-12 Banyu Pharmaceut Co Ltd 抗腫瘍剤
JPH06100405A (ja) * 1992-08-07 1994-04-12 Yoshitomi Pharmaceut Ind Ltd 水中防汚剤
WO1998011889A1 (de) 1996-09-18 1998-03-26 Marigen S.A. Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral, antiviral, viruzid und antiparasitär wirksamen estern von bioflavonoid-verbindungen
ID26031A (id) 1998-03-26 2000-11-16 Shionogi & Co Turunan indol yang memiliki suatu aktivitas antiviral
WO1999062897A1 (en) 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
AU4225499A (en) 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
CA2329134A1 (en) 1998-06-03 1999-12-09 David L. Clark Hiv integrase inhibitors
CA2348734A1 (en) 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
AU763040B2 (en) 1998-12-25 2003-07-10 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
EP1196384A4 (en) 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
JP4577751B2 (ja) 1999-09-02 2010-11-10 塩野義製薬株式会社 芳香族ヘテロ環誘導体を含有するインテグラーゼ阻害剤
JP2001270884A (ja) 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1326611B1 (en) 2000-10-12 2007-06-13 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
KR20030036922A (ko) 2000-10-12 2003-05-09 머크 앤드 캄파니 인코포레이티드 Ｈｉｖ 인테그라제 억제제로서 유용한 아자- 및폴리아자-나프탈레닐 카복스아미드
EP1333831A2 (en) 2000-10-12 2003-08-13 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
JP4176477B2 (ja) 2001-03-01 2008-11-05 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環誘導体
CA2439666A1 (en) 2001-03-01 2002-09-12 Shionogi & Co., Ltd. Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
US20040229909A1 (en) 2001-08-10 2004-11-18 Ryuichi Kiyama Antiviral agent
KR20040048936A (ko) * 2001-10-03 2004-06-10 유씨비 소시에떼아노님 피롤리디논 유도체
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2554120A1 (en) 2004-01-30 2005-08-18 Merck & Co., Inc. N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040039060A1 (en) * 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US20050025774A1 (en) * 2001-10-26 2005-02-03 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7745453B2 (en) * 2003-12-22 2010-06-29 Shionogi & Co., Ltd. Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Exp. Opin. Invest. Drugs, 2001; 10(2):281-296; published February 2001 *
Pyrimidine - IUPAC Gold Book 1995 *

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572813B2 (en) 2001-08-10 2017-02-21 Shionogi & Co., Ltd. Antiviral agent
US7217713B2 (en) 2001-10-26 2007-05-15 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US20050025774A1 (en) * 2001-10-26 2005-02-03 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7820660B2 (en) 2001-10-26 2010-10-26 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US20110034449A1 (en) * 2001-10-26 2011-02-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
US7459452B2 (en) 2001-10-26 2008-12-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US20060258860A1 (en) * 2001-10-26 2006-11-16 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US7169780B2 (en) 2001-10-26 2007-01-30 Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US20070083045A1 (en) * 2001-10-26 2007-04-12 Di Francesco Maria E Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US20080275004A1 (en) * 2001-10-26 2008-11-06 Benedetta Crescenzi N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US20070123524A1 (en) * 2001-10-26 2007-05-31 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US7232819B2 (en) 2001-10-26 2007-06-19 Istituto Di Ricerche Di Biologia P. Angeletti S.P.A. Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US7435734B2 (en) 2001-10-26 2008-10-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
US20050075356A1 (en) * 2001-10-26 2005-04-07 Di Francesco Maria E. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US20060046985A1 (en) * 2002-12-27 2006-03-02 Benedetta Crescenzi Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors
US7968553B2 (en) 2002-12-27 2011-06-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors
US7414045B2 (en) 2002-12-27 2008-08-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
US20100204237A1 (en) * 2003-12-22 2010-08-12 Hidenori Mikamiyama Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase
US7745453B2 (en) 2003-12-22 2010-06-29 Shionogi & Co., Ltd. Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase
US20070155744A1 (en) * 2004-01-30 2007-07-05 Istituto Di Ricerche Di Biologia Molecolare P, Angeletti S.P.A. N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4- carboxamide compounds useful as hiv integrase inhibitors
US7598264B2 (en) 2004-03-09 2009-10-06 Merck & Co., Inc. HIV integrase inhibitors
US7820680B2 (en) 2004-03-09 2010-10-26 Merck & Co., Inc. HIV integrase inhibitors
US20090099168A1 (en) * 2004-03-09 2009-04-16 Monica Donghi HIV Integrase inhibitors
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
US20080139579A1 (en) * 2004-03-09 2008-06-12 Merck & Co., Inc. Hiv Integrase Inhibitors
US20070179196A1 (en) * 2004-03-09 2007-08-02 Wei Han Hiv integrase inhibitors
US7619086B2 (en) 2004-03-09 2009-11-17 Merck & Co., Inc. HIV integrase inhibitors
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
US20080287394A1 (en) * 2004-05-07 2008-11-20 Merck & Co., Inc. Hiv Integrase Inhibitors
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US20050261322A1 (en) * 2004-05-18 2005-11-24 Naidu B N HIV integrase inhibitors
US7476666B2 (en) 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
US20080015187A1 (en) * 2004-06-09 2008-01-17 Wai John S Hiv Integrase Inhibitors
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
US20070249687A1 (en) * 2004-09-15 2007-10-25 Hiroshi Yoshida Carbamoylpyridone Derivatives Having Inhibitory Activity Against Hiv Integrase
US7858788B2 (en) 2005-02-21 2010-12-28 Shionogi & Co., Ltd. Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
US20080161271A1 (en) * 2005-02-21 2008-07-03 Hiroshi Yoshida Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity
US7981879B2 (en) 2005-03-31 2011-07-19 Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. HIV integrase inhibitors
US20100204201A1 (en) * 2005-05-10 2010-08-12 Vacca Joseph P Hiv integrase inhibitors
US7741315B2 (en) 2005-05-10 2010-06-22 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US8293731B2 (en) 2005-05-10 2012-10-23 Merck Sharp + Dohme Corp. HIV integrase inhibitors
US7968564B2 (en) 2005-05-10 2011-06-28 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US20090054399A1 (en) * 2005-05-10 2009-02-26 Vacca Joseph P Hiv integrase inhibitors
US20090221571A1 (en) * 2005-10-04 2009-09-03 Vincenzo Summa Hiv integrase inhibitors
US7939537B2 (en) 2005-10-04 2011-05-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HIV integrase inhibitors
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
US20110130397A1 (en) * 2006-09-22 2011-06-02 Soongyu Choi Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
US20100216834A1 (en) * 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
US8431581B2 (en) 2008-07-02 2013-04-30 Avexa Limited Imidazopyrimidines and uses thereof
US20110039842A1 (en) * 2008-07-02 2011-02-17 John Joseph Deadman Compounds having antiviral properties
US20110028487A1 (en) * 2008-07-02 2011-02-03 Avexa Limited Imidazopyrimidines and uses thereof
WO2010000031A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones and uses thereof
WO2010000032A1 (en) 2008-07-02 2010-01-07 Avexa Limited Compounds having antiviral properties
US8318732B2 (en) 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
AU2009266421B2 (en) * 2008-07-02 2013-07-11 Avexa Limited Compounds having antiviral properties
US8563562B2 (en) 2008-07-02 2013-10-22 Avexa Limited Compounds having antiviral properties
EP2759544A1 (en) 2008-07-02 2014-07-30 Avexa Limited Compounds having antiviral properties
WO2010000030A1 (en) 2008-07-02 2010-01-07 Avexa Limited Thiazopyrimidinones and uses thereof
US20100087419A1 (en) * 2008-10-06 2010-04-08 Isaacs Richard C A Hiv integrase inhibitors
US8513234B2 (en) 2008-10-06 2013-08-20 Merck Sharp & Dohme Corp. HIV integrase inhibitors
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9120794B2 (en) 2011-09-27 2015-09-01 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
EP3330272A1 (en) 2013-05-17 2018-06-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2015048363A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US10201533B2 (en) 2013-09-27 2019-02-12 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
US9861620B2 (en) 2013-09-27 2018-01-09 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
WO2015117094A1 (en) * 2014-02-03 2015-08-06 American Life Science Pharmaceuticals, Inc. Compositions and methods for synthesizing (2s,3s)-trans-epoxysuccinyl-l-leucyl-amido-3-methylbutane ethyl ester
US10065930B2 (en) 2014-08-06 2018-09-04 Eisai R&D Management Co., Ltd. Method for producing pyrimidine-1-ol compound, and intermediate thereof
RU2681937C2 (ru) * 2014-08-06 2019-03-14 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения пиримидин-1-олового соединения и его промежуточного соединения
WO2016191239A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017116928A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2017190050A1 (en) * 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
CN107773562A (zh) * 2016-08-25 2018-03-09 清华大学 化合物在抗登革和寨卡病毒感染中的应用
WO2018102485A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
CN110431224A (zh) * 2017-03-13 2019-11-08 帝斯曼知识产权资产管理有限公司 锌双核簇转录调控因子缺陷型菌株

Also Published As

Publication number Publication date
DK2266958T1 (da) 2016-04-04
JP5207392B2 (ja) 2013-06-12
DE10178132T1 (de) 2016-06-23
EP1422218B1 (en) 2012-03-21
CN1558898A (zh) 2004-12-29
KR20100087209A (ko) 2010-08-03
PT2266958T (pt) 2017-05-10
DK3042894T1 (da) 2016-11-07
JP2012236852A (ja) 2012-12-06
ES2572030T3 (es) 2017-07-19
KR20040023749A (ko) 2004-03-18
CN101513402A (zh) 2009-08-26
WO2003016275A1 (en) 2003-02-27
JP4338192B2 (ja) 2009-10-07
CY20162200001T2 (el) 2016-07-27
MXPA04000646A (es) 2004-03-18
TWI327137B (enrdf_load_stackoverflow) 2010-07-11
CN100491349C (zh) 2009-05-27
EP2181985B1 (en) 2011-10-26
JPWO2003016275A1 (ja) 2004-12-02
ES2587564T1 (es) 2016-10-25
EP2181985A1 (en) 2010-05-05
US20150202208A1 (en) 2015-07-23
US9572813B2 (en) 2017-02-21
EP2266958B1 (en) 2017-03-15
JP2009161556A (ja) 2009-07-23
KR100977701B1 (ko) 2010-08-24
EP2266958A1 (en) 2010-12-29
EP1422218A1 (en) 2004-05-26
US20170066754A1 (en) 2017-03-09
CA2452769A1 (en) 2003-02-27
EP1422218A4 (en) 2005-11-30
DE15187654T1 (de) 2016-12-01
BR0211750A (pt) 2004-10-13
ATE550320T1 (de) 2012-04-15
ES2383262T3 (es) 2012-06-19
CN101513402B (zh) 2012-03-21
EP3042894A1 (en) 2016-07-13
ATE530520T1 (de) 2011-11-15
CA2452769C (en) 2012-08-21
ES2572030T1 (es) 2016-05-27
CY20162200002T2 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
US9572813B2 (en) Antiviral agent
US11447453B2 (en) Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
DE60115069T2 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
KR100274104B1 (ko) 포스포디에스테라제 억제제로서의 피리도[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR970005906B1 (ko) 리폭시게나제 억제 화합물을 함유하는 푸란 및 피톨
WO2005009941A1 (en) Indane derivates as muscarinic receptor agonists
JP2024521141A (ja) Ｋａｔ６ａ阻害剤としての縮合イソオキサゾリル化合物
DE69113115T2 (de) Dioxo-tetrahydrochinolinderivate.
US20200055824A1 (en) Wdr5-mll1 inhibitors and modulators
JP2024502056A (ja) ＲＯＲγｔモジュレーター、その製造方法および応用
AU2015215863C1 (en) Inhibitors of jun n-terminal kinase
HK1167655B (en) Inhibitors of jun n-terminal kinase

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHIONOGI & CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIYAMA, RYUICHI;KANDA, YASUHIKO;TADA, YUKIO;AND OTHERS;REEL/FRAME:015536/0910

Effective date: 20031127

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION